Winston J.A., Bruggeman L.A., Ross M.D. et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N. Engl. J. Med., 2001, No. 344, pp. 1979–1984.

Беляков Н.А., Рассохин В.В., Трофимова Т.Н., Степанова Е.В., Пантелеев А.М., Леонова О.Н., Бузунова С.А., Коновалова Н.В., Миличкина А.М., Тотолян А.А. Коморбидные и тяжелые формы ВИЧ-инфекции в России // ВИЧ-инфекция и иммуносупрессии. 2016. Т. 8, № 3. С. 9–24

Леонова О.Н., Степанова Е.В., Беляков Н.А. Тяжелые и коморбидные состояния у больных с ВИЧ-инфекцией: анализ неблагоприятных исходов // ВИЧ-инфекция и иммуносупрессии. 2017. Т. 9, № 1. С. 55–64.

Daugas E., Rougier J.P., Hill G. HAART-related nephropathies in HIV infected patients. Kidney Int., 2005, No. 67, pp. 393–403.

Wyatt C.M., Klotman C.E. Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection. Expert. Opin. Drug. Saf., 2006, No. 5, pp. 275–287.

Национальные клинические рекомендации «Хроническая болезнь почек у ВИЧ-инфицированных пациентов (причины, диагностика, принципы ведения)» / Г.В.Волгина, М.М.Гаджикулиева. М., 20157.

Franceschini N., Napravnik S., Eron J.J. Jr., Szczech L.A., Finn W.F. Incidence and etiology of acute renal failure among ambulatory HIV infected patients. Kidney Int., 2005, Vol. 67 (4), pp. 1526–1531.

Tungsiripat M. & Aberg J.A. Dyslipidemia in HIV patients. Cleveland Clin. J. Med., 2005, No. 72, pp. 1113–1120.

Heffelfinger J., Hanson D., Voetsch A. et al. Renal impairment associated with the use of tenofovir. 13th CROI 2006. Abstract 779, Denver, USA, 2006.

Szczech L.A., Gange S.J., van der Horst C., Bartlett J.A., Young M., Cohen M.H., Anastos K., Klassen P.S., Svetkey L.P. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int., 2002, Vol. 61 (1), pp. 195–202. DOI: 10.1046/j.1523–1755.2002.00094.x..
DOI: 10.1046/j.1523–1755.2002.00094.x

Mocroft A., Phillips A.N., Gatell J. et al. 14th CROI, Abstract 828, Los Angeles, CA, 2007.

Krawczyk C.S., Holmberg S.D., Moorman A.C. et al. HIV Outpatient Study Group. Factors associated with chronic renal failure in HIV-infected ambulatory patients. AIDS, 2004, No. 18, pp. 2171–2178.HIV Infection and Immunosuppressive Disorders, 2018, Vol. 10, No. 2 40

Overton E. et al. Factors associated with renal dysfunction within an urban cohort in the era of HAART. 14th CROI 2007, Abstract 826, Los Angeles, CA, 2007.

Ющук Н.Д., Волгина Г.В., Томилина Н.А., Гаджикулиева М.М., Кочарян К.А. Нефротоксические эффекты высокоактивной антиретровирусной терапии (Обзор литературы) // Нефрология и диализ. 2010. Т. 12, № 3. С. 154– 163.

Laurinavicius A., Rennke H.G. Collapsing glomerulopathy — a new pattern of renal injury. Semin. Diagn. Pathol., 2002, Vol. 19 (3), pp. 106–115..
DOI: 10.1046/j.1523–1755.2002.00094.x

Green S.T., McKendrick M.W., Schmid M.L., Mohsen A.H., Prakasam S.F. Renal calculi developing de novo in a patient taking saquinavir. Int. J. STD AIDS, 1998, No. 9, pp. 555..
DOI: 10.1046/j.1523–1755.2002.00094.x

Engeler D.S., John H., Rentsch K.M., Ruef C., Oertle D., Suter S. Nelfinavir urinary stones. J. Urol., 2002, No. 167, pp. 1384–1385.

DocoLecompte T., Garrec A., Thomas L., Trechot P., May T., Rabaud C. Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. AIDS, 2004, No. 18, pp. 705–706.

Crixivan (Indinavir Sulfate): Full Prescription Information (Package Insert). Whitehouse station: Merck & Co, 2013.

Scherzer R., Estrella M., Li Y., Deeks S.G., Grunfeld C., Shlipak M.G. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS, 2012, No. 26, pp. 867–875.

Mocroft A., Kirk O., Reiss P. et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS, 2010, Vol. 24 (11), pp. 1667–1678.

Fogo A.B., Lusco M.A., Najafian B., Alpers C.E. AJKD — Atlas of Renal Pathology: HIV-Associated Immune Complex Kidney Disease (HIVICK). Am. J. Kidney Diseases, 2016, Vol. 8 (2), pp. e9–e10. DOI: 10.1053/j.ajkd.2016.06.003..
DOI: 10.1053/j.ajkd.2016.06.003

Daudon M., Estepa L., Viard J.P. et al. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet, 1997, No. 349, pp. 1294–1295.

Molina J.-M., Andrade-Villanueva J., Echevarria J. et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy an d safety results of the CASTLE study. J. Acquir. Immune Defic. Syndr., 2010, No. 53, pp. 323–332.

Clumeck N., Pozniak A., Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med., 2008, No. 9, pp. 65–71.

Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Ермак Т.Н., Канестри В.Г., Шахгильдян В.И., Козырина Н.В., Буравцова Е.В., Нарсия Р.С., Покровская А.В., Ефремова О.С., Коннов В.В., Куимова У.А., Попова А.А., Хохлова О.Н., Воронин Е.Е., Афонина Л.Ю., Васильева И.А., Зимина В.Н. Национальные рекомендации по диспансерному наблюдению и лечению больных ВИЧинфекцией // Эпидемиология инфекционных болезней. Актуальные вопросы. 2015. № 6. Приложение. 72 с. [

Molina J.M., Andrare-Villanueva J., Echevarria J. et al. Atazanavir/ritonavir vs lopinavir/ritonavir in antiretroviral-naive HIV-1-infected patients: CASTLE 96 week efficacy and safety. Program and abstracts of the 48th Annual ICAAC/IDSA 46th Annual Meeting, October 25–28, 2008, Abstract H-1250d, Washington, DC, 2008.

Reyataz (Atazanavir Sulfate): Full Prescription Information (Package Insert). Princeton, N. J.: Bristol-Myers Squibb, 2012.

Pacanowski J., Poirier J.M., Petit I. et al. Atazanavir urinary stones in an HIV-infected patient. AIDS, 2006, Vol. 20 (16), pp. 2131.

Chan-Tack K.M., Truffa M.M., Struble K.A. et al. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration’s Adverse Event Reporting System. AIDS, 2007, Vol. 21 (9), pp. 1215–1218.

Couzigou C., Daudon M., Meynard J.L. et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin. Infect. Dis., 2007, Vol. 45 (8), pp. 105–108.

Lastours V., De Silva E.F.R., Daudon M., Porcher R., Loze B., Sauvageon H., Molina J.M. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J. Antimicrob. Chemother., 2013, No. 68, pp. 1850–1856.

Gervasoni C., Meraviglia P., Minisci D., Ferraris L., Riva A., Landonio S., Cozzi V., Charbe N., Molinari L., Rizzardini G., Clementi E., Galli M., Cattaneo M. Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages? PLoS One, 2015, Vol. 10 (4), pp. e0123670.

Hamada Y., Nishijima T., Watanabe K., Komatsu H., Tsukada K., Teruya K., Kikuchi Y., Oka S. High Incidence of Renal Stones Among HIVInfected Patients on Ritonavir-Boosted Atazanavir Than in Those Receiving Other Protease Inhibitor – Containing Antiretroviral Therapy. HIV/AIDS, 2012, No. 55, pp. 1262–1269.

Lin K.-Y., Liao S.-H., Liu W.-C., Cheng A., Lin S.-W., Chang S.-Y., Tsai M.-S., Kuo C.-H., Wu M.-R., Wang H.-P., Hung C.-C., Chang S.-C. Cholelithiasis and Nephrolithiasis in HIVPositive Patients in the Era of Combination Antiretroviral Therapy. PLoS One, 2015, Vol. 10 (9), pp. e0137660. DOI: 10.1371/journal.pone.0137660..
DOI: 10.1371/journal.pone.0137660

Hegde S., Singh C., Ohare B. HIV-associated nephropathy in the setting of maximal virologic suppression. Pediatric Nephrology, 2011, Vol. 26, No. 6, pp. 973–977.

Choi A.I., Shlipak M.G., Hunt P.W., Martin J.N., Deeks S.G. HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS, 2009, Vol. 23, No. 16, pp. 2143–2149.

Postorino M.C., Quiros-Roldan E., Maggiolo F., DiGiambenedetto S., Ladisa N. et al. and The MASTER study group. Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function. The Open AIDS Journal, 2016, No. 10, pp. 136–143. DOI: 10.2174/1874613601610010136..
DOI: 10.2174/1874613601610010136

Raheem O.A., Mirheydar H.S., Palazzi K., Chenoweth M., Lakin C., Sur R.L. Prevalence of nephrolithiasis in human immunodeficiency virus infected patients on the highly active antiretroviral therapy. Journal of Endouroloy, 2012, Vol. 26, No. 8, pp. 1095–1098. DOI: 10.1089/end.2011.0639..
DOI: 10.1089/end.2011.0639

Raheem O.A., Mirheydar H.S., Palazzi K., Chenoweth M., Lakin C., Sur R.L. Prevalence of nephrolithiasis in human immunodeficiency virus infected patients on the highly active antiretroviral therapy. Journal of Endouroloy, 2012, Vol. 26, No. 8, pp. 1095–1098. DOI: 10.1089/end.2011.0639..
DOI: 10.1053/j.ajkd.2016.06.003

Cooper R.D., Wiebe N., Smith N., Keiser P., Naicker S., Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin. Infect. Dis., 2010, Vol. 51 (5), pp. 496–505..
DOI: 10.1053/j.ajkd.2016.06.003

Scherzer R., Estrella M., Li Y., Deeks S.G., Grunfeld C., Shlipak M.G. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS, 2012, No. 26, pp. 867–875.

Mugwanya K.K., Wyatt C., Celum C. et al. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. JAMA Int. Med., 2015, Vol. 175 (2), pp. 246–254.

Solomon M.M., Lama J.R., Glidden D.V. et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS, 2014, Vol. 28 (6), pp. 851–859.

ВИЧ 2016/17 / Под ред. К.Хоффмана и Ю.К.Рокштро. URL: www.hivbuch.de.www.hivbuch.de

Sax P.E., Wohl D., Yin M.T. et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet, 2015, Vol. 385 (9987), pp. 2606–2615.

Wohl D., Oka S., Clumeck N. et al. Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. AIDS, 2016, Vol. 72 (1), pp. 58–64.

Mills A., Arribas J.R., Andrade-Villanueva J. et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect. Dis., 2016, Vol. 16 (1), pp. 43–52.

Pozniak A., Arribas J.R., Gathe J. et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. AIDS, 2016, Vol. 71 (5), pp. 530–537.

Karras A., Lafaurie M., Furco A. et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin. Infect. Dis., 2003, Vol. 36 (8), pp. 1070–1073.

Rifkin B.S., Perazella M.A. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am. J. Med., 2004, Vol. 117 (4), pp. 282–284.

Verhelst D., Monge M., Meynard J.L. et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am. J. Kidney Dis., 2002, Vol. 40 (6), pp. 1331–1333.

James C.W., Steinhaus M.C., Szabo S. et al. Tenofovir-related nephrotoxicity: Case report and review of the literature. Pharmacotherapy, 2004, Vol. 24 (3), pp. 415–418.

Braun D.L., Kouyos R.D., Balmer B., Grube C., Weber R., Günthard H.F. Frequency and spectrum of unexpected clinical manifestations of primary HIV-1 infection. Clin. Infect. Dis., 2015, pii: civ398. [Epub ahead of print].

Bellomo R. The epidemiology of acute renal failure: 1975 versus 2005. Curr. Opin. Crit. Care, 2006, Vol. 12 (6), pp. 557–560.

Leblanc M., Kellum J.A., Gibney R.T. et al. Risk factors for acute renal failure: inherent and modifiable risks. Curr. Opin. Crit. Care, 2005, Vol. 11 (6), pp. 533–536.

Roe J., Campbell L.J., Ibrahim F. et al. HIV care and the incidence of acute renal failure. Clin. Infect. Dis., 2008, Vol. 47 (2), pp. 242–249.

Wyatt C.M. Acute renal failure in hospitalized patients with HIV: risk factors and impact on inhospital mortality. AIDS, 2006, Vol. 20 (4), pp. 561–565.

Нефрология. Основы диагностики / Под ред. В.П.Терентьева. Ростов-на-Дону: Феникс, 2003.

Gupta S., Eustace J.A., Winston J.A. et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis., 2005, No. 40, pp. 1559–1585.

Гоженко А.И., Горобець О.П., Гойдик В.С., Сервецкий С.К., Гуменюк Р.В. Мочевой синдром у ВИЧ-инфицированных больных в стадии СПИДа // Нефрология. 2008. Т. 12, № 4. С. 54–58.

Wyatt C.M., Hoover D.R., Shi Q. et al. Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. AIDS, 2010, No. 55, pp. 73–77.

Winston J., Deray G., Hawkins T. et al. Kidney disease in patients with HIV Infection and AIDS. Clin. Infect. Dis., 2008, No. 47, pp. 1449–1457.

Бондаренко В.Н., Буйневич И.В., Морозов Ю.А., Марченко Т.В., Медников Р.В., Кижло С.Н. Оценка функции почек у ВИЧ-инфицированных пациентов: креатинин или цистатин С? (Oбзор литературы) // Проблемы здоровья и экологии. 2014. № 3 (41). С. 15–18.

Inker L.A., Wyatt C., Creamer R. et al. Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals. AIDS, 2012, Vol. 61 (3), pp. 302–309.

Gagneux-Brunon A., Delanaye P., Maillard N. et al. Performance of creatinine and cystatin C-based glomerular filtration rate estimating equations in a European HIV-positive cohort. AIDS, 2013, Vol. 27 (10), pp. 1573–1581..
DOI: 10.1371/journal.pone.0137660

Bhasin B., Lau B., Atta M.G. et al. HIV viremia and T-cell activation differentially affect the performance of glomerular filtration rate equations based on creatinine and cystatin C. PLoS One, 2013, Vol. 8 (12), pp. e82028..
DOI: 10.1371/journal.pone.0137660

Jones C.Y., Jones C.A., Wilson I.B., Knox T.A., Levey A.S., Spiegelman D., Gorbach S.L., Van Lente F., Stevens L.A. Cystatin C and creatinine in an HIV cohort: the nutrition for healthy living study. Am. J. Kidney Dis., 2008, No. 51, pp. 914–924.

Mauss S., Berger F., Kuschak D. еt al. Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients. Antivir. Ther., 2008, No. 13, pp. 1091–1095.

Overton E.T., Nurutdinova D., Freeman J. еt al. Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. HIV Med., 2009, No. 10, pp. 343–350.

Дж.Бартлетт, Дж.Галлант, П.Фам. Клинические аспекты ВИЧ-инфекции 2009–2010. М.: Р.Валент, 2010. 490 c. [Eds. J.Bartlett, J.Gallant, P. Pham. Clinical aspects of HIV infection 2009–2010. Moscow: R.Valente, 2010, 490 p. (In Russ.)].

Abraham A.G., Althoff K.N., Jing Y., Estrella M.M., Kitahata M.M., Wester C.W., Bosch R.J., Crane H., Eron J., Gill M.J., Horberg M.A., Justice A.C., Klein M., Mayor A.M., Moore R.D., Palella F.J., Parikh C.R., Silverberg M.J., Golub E.T., Jacobson L.P., Napravnik S. and Lucas G.M., for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA). End-Stage Renal Disease Among HIV-Infected Adults in North America. HIV/AIDS. CID, 2015, No. 60, pp. 941–943..
DOI: 10.2174/1874613601610010136

Atta M.G., Choi M.J., Longenecker J.C. et al. Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy. Am J. Med., 2005, No. 118, pp. 1288–1289..
DOI: 10.2174/1874613601610010136